Evidence map›Paper›PMID 23770848›Full record

ArticleOncogene2014

Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin.

L Damiano, K M Stewart, N Cohet, J K Mouw, J N Lakins, J Debnath, D Reisman, J A Nickerson, A N Imbalzano, V M Weaver

RetractedAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Trial
  3. Article
  4. Article
  5. Hypoxia Selectively Enhances Integrin αMolecular cancer research : MCR · 2017
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

L DamianoDepartment of Surgery, Center for Bioengineering and Tissue Regeneration, University of California-San Francisco, San Francisco, CA, USA.
K M StewartDepartment of Surgery, Center for Bioengineering and Tissue Regeneration, University of California-San Francisco, San Francisco, CA, USA.
N CohetDepartment of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
J K MouwDepartment of Surgery, Center for Bioengineering and Tissue Regeneration, University of California-San Francisco, San Francisco, CA, USA.
J N LakinsDepartment of Surgery, Center for Bioengineering and Tissue Regeneration, University of California-San Francisco, San Francisco, CA, USA.
J DebnathDepartment of Pathology, University of California-San Francisco, San Francisco, CA, USA.
D ReismanDivision of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA.
J A NickersonDepartment of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
A N ImbalzanoDepartment of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA, USA.
V M Weaver1] Department of Surgery, Center for Bioengineering and Tissue Regeneration, University of California-San Francisco, San Francisco, CA, USA [2] Department of Anatomy, Bioengineering and Therapeutic Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA.
University of California, San Francisco · USUniversity of Massachusetts Chan Medical School · USUniversity of Florida · US

Funding

SUBNUCLEAR TARGETING OF TRANSCRIPTION FACTORSP01CA082834 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STEIN, GARY S. · 2001 to 2015
$18.4M
TRANS-NETWORK PROJECTSU54CA143836 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIPHARDT, JAN T. · 2009 to 2014
$15.1M
TGF BETA SUPPRESSION AND PROMOTION OF MAMMARY CARCINOMASR01CA085492 · NCI · VANDERBILT UNIVERSITY · PI MOSES, HAROLD L, WEAVER, VALERIE MARIE · 2000 to 2015
$6.4M
The vascular niche in glioma propagation and resistance to therapyU54CA163155 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE, WEAVER, VALERIE MARIE · 2011 to 2015
$4.4M
Environmental Effect on the Mammary Gland across the LifespanU01ES019458 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 2010 to 2014
$2.5M
Collagen remodeling and tumor progressionR01CA138818 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEAVER, VALERIE MARIE · 2010 to 2014
$2.0M
NCI NIH HHS P01 CA082834NCI NIH HHS R01 CA085492NCI NIH HHS R01 CA138818NCI NIH HHS U54 CA143836NCI NIH HHS U54 CA163155NIEHS NIH HHS U01 ES019458NIEHS NIH HHS U01ES019458
6 · The paper itself

Abstract

Integrin expression and activity are altered in tumors, and aberrant integrin signaling promotes malignancy. However, how integrins become altered in tumors remains poorly understood. We discovered that oncogenic activation of MEK signaling induces cell growth and survival, and promotes the malignant phenotype of mammary epithelial cells (MECs) by increasing α5 integrin expression. We determined that MEK activates c-Myc to reduce the transcription of the SWI/SNF chromatin remodeling enzyme Brahma (BRM). Our studies revealed that reduced BRM expression and/or activity drives the malignant behavior of MECs by epigenetically promoting C/EBPβ expression to directly induce α5 integrin transcription. Consistently, we could show that restoring BRM levels normalized the malignant behavior of transformed MECs in culture and in vivo by preventing C/EBPβ-dependent α5 integrin transcription. Our findings identify a novel mechanism whereby oncogenic signaling promotes malignant transformation by regulating transcription of a key chromatin remodeling molecule that regulates integrin-dependent stromal-epithelial interactions.

Indexed as

Breast NeoplasmsCCAAT-Enhancer-Binding Protein-betaCell AdhesionCell Line, TumorCell Transformation, NeoplasticChromatin ImmunoprecipitationEpithelial CellsFlow CytometryFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansImmunoblottingIntegrin alpha5Real-Time Polymerase Chain ReactionRNA, Small InterferingTranscription FactorsCCAAT-Enhancer-Binding Protein-betaIntegrin alpha5RNA, Small InterferingSMARCA2 protein, humanTranscription Factors

Identifiers

PMID23770848
PMCPMC3960370
OpenAlexW1983752059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.